全文获取类型
收费全文 | 2163篇 |
免费 | 221篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 121篇 |
妇产科学 | 29篇 |
基础医学 | 280篇 |
口腔科学 | 72篇 |
临床医学 | 298篇 |
内科学 | 395篇 |
皮肤病学 | 24篇 |
神经病学 | 249篇 |
特种医学 | 190篇 |
外科学 | 297篇 |
综合类 | 77篇 |
预防医学 | 117篇 |
眼科学 | 8篇 |
药学 | 108篇 |
中国医学 | 7篇 |
肿瘤学 | 104篇 |
出版年
2023年 | 14篇 |
2022年 | 13篇 |
2021年 | 31篇 |
2020年 | 14篇 |
2019年 | 22篇 |
2018年 | 53篇 |
2017年 | 61篇 |
2016年 | 61篇 |
2015年 | 60篇 |
2014年 | 71篇 |
2013年 | 122篇 |
2012年 | 90篇 |
2011年 | 79篇 |
2010年 | 107篇 |
2009年 | 81篇 |
2008年 | 81篇 |
2007年 | 69篇 |
2006年 | 88篇 |
2005年 | 61篇 |
2004年 | 70篇 |
2003年 | 61篇 |
2002年 | 44篇 |
2001年 | 53篇 |
2000年 | 50篇 |
1999年 | 29篇 |
1998年 | 69篇 |
1997年 | 63篇 |
1996年 | 60篇 |
1995年 | 56篇 |
1994年 | 36篇 |
1993年 | 51篇 |
1992年 | 48篇 |
1991年 | 44篇 |
1990年 | 43篇 |
1989年 | 31篇 |
1988年 | 45篇 |
1987年 | 47篇 |
1986年 | 37篇 |
1985年 | 27篇 |
1984年 | 27篇 |
1983年 | 28篇 |
1981年 | 21篇 |
1980年 | 23篇 |
1979年 | 13篇 |
1978年 | 12篇 |
1977年 | 19篇 |
1976年 | 20篇 |
1975年 | 16篇 |
1974年 | 10篇 |
1973年 | 9篇 |
排序方式: 共有2394条查询结果,搜索用时 0 毫秒
61.
62.
Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody 总被引:1,自引:1,他引:1
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC 《Blood》1994,83(6):1632-1639
Antigenic modulation is one of many factors determining the effectiveness of monoclonal antibody (MoAb)-mediated therapy. To select the isotype of a CD19 MoAb most suitable for radioimmunotherapy of patients with B-cell malignancies, we studied the influence of MoAb isotype on modulation, after binding of the MoAb to different cell-line cells. The CD19-IgG1 MoAb was found to induce modulation of CD19 antigens on Daudi cell line cells more rapidly than did its IgG2a switch variant. We provide evidence that this difference in modulation rate is caused by the expression of Fc gamma receptor II (Fc gamma RII) on these cells. Experiments aimed at elucidating the mechanism of Fc gamma RII involvement in modulation induction by CD19-IgG1 showed that Fc gamma RII did not comodulate with CD19 MoAbs. However, cocrosslinking of CD19 and Fc gamma RII with CD19-IgG1 MoAb resulted in enhanced calcium mobilization in Daudi cells. This increased signal induction accompanies the enhanced capping and subsequent modulation of CD19 antigens. Because Fc gamma RII is expressed in varying densities on malignant B cells in all differentiation stages, our results have implications for the MoAb isotype most suitable for use in MoAb-based therapy of patients with B-cell malignancies. 相似文献
63.
A sensitive and precise radioreceptor assay for determining plasma levels of human factor VIII/von Willebrand's factor (FVIII/vWF) has been developed by taking advantage of the FVIII/vWF receptor sites on human platelets. Paraformaldehyde-fixed platelets, which were processed and then stored, retained FVIII/vWF binding activity and therefore could be used as a convenient source of receptors. The human plasma samples to be tested were initially filtered on 4% agarose columns to concentrate the FVIII/vWF protein in the void volume and to remove the factor(s) that interferes with the assay. The percent recovery of FVIII/vWF in the pooled eluent was measured by the recovery of added trace 125I-FVIII/vWF. The coefficients of intra- and interassay variation were 6% and 10%, respectively. The plasma FVIII/vWF concentrations determined by the assay for pooled normal plasma, hemophilia A plasma, and plasmas from two patients with von Willebrand's disease were 16.3 +/- 0.5, 52.6 +/- 1.5, 6.8 +/- 0.8, and 3.2 +/- 0.2 microgram/ml, respectively. The range of plasma FVIII/vWF concentrations varied between 8.3 microgram/ml and 24.9 microgram/ml for 10 normal adults. The plasma FVIII/vWF concentrations determined by the radioreceptor assay correlated well with levels measured by the ristocetin-induced platelet aggregation method, thus demonstrating the functional relevancy of the radioreceptor assay for plasma FVIII/vWF. 相似文献
64.
65.
Long‐term efficacy of a 0.07% cetylpyridinium chloride mouth rinse in relation to plaque and gingivitis: a 6‐month randomized,vehicle‐controlled clinical trial 下载免费PDF全文
66.
BO Motayo PA Akinduti FA Adeyakinu PO Okerentugba JC Nwanze CC Onoh HC Innocent-Adiele IO Okonko 《African health sciences》2013,13(4):1091-1097
Background
The increased reports of ESBL dissemination from various centres in south western, Nigeria and the recent emergence of carbapenem resistant bacteria prompted the conception of this study.Objectives
To demonstrate the relationship between high molecular weight plasmids and the expression of antibiotic multi-resistance including ESBL and carbapenemase.Methods
We investigated 97 isolates of selected organisms consisting of 67 E. coli and 30 Klebseilla spp for the presence of plasmids expressing ESBL including carbapenem-hydrolysing enzymes. Beta-lactamase was determined using acidometric method, while ESBL and carbapenemase activity was determined using the double-disk diffusion test as well as the Modified Hodge test (MHT). Plasmid profiles of ESBL and carbapenemase positive isolates were determined according to standard protocols.Results
An ESBL prevalence rate of 21.6% and carbapenem- resistance rate of 9.3% was recorded. Antibiotic susceptibility profile of ESBL isolates showed 100.0% resistance against Amoxicillin, Cotrimoxazole and Erythromycin. Moderate susceptibility was recorded against the Quinolone class of antibiotics; Meropenem remained the most active antibiotic against ESBL isolates with 62.5% against E. coli and 60% against K. pneumoniae. The plasmid profiles of our study isolates ranged from 11.8kbp to 35.5kbp.Conclusion
Due to the relationship between high molecular weight plasmids and multi-drug resistance, we hereby recommend regular molecular surveillance of this form in our study setting. 相似文献67.
68.
69.
非酒精性脂肪性肝炎(non—alcoholicsteatohepatitis,NASH)现已成为肝移植愈来愈重要的基础肝病。鉴于晚期NASH患者常并存多种影响肝移植转归的临床问题,而至今尚无针对NASH患者进行肝移植的评估和治疗指南,为此英国移植学会(British Transplant Society,BTS)邀请相关专家制定了指南,以指导肝移植前后NASH患者的处理。 相似文献
70.
Patrick L. Wagner MD Frances Austin MD Ugwuji Maduekwe MD Arun Mavanur MD Lekshmi Ramalingam MD Heather L. Jones PA Matthew P. Holtzman MD Steven A. Ahrendt MD Amer H. Zureikat MD James F. Pingpank MD Herbert J. Zeh MD David L. Bartlett MD Haroon A. Choudry MD 《Annals of surgical oncology》2013,20(4):1056-1062